Document is current
Any future updates will be listed below
-
Authors
Rizzi, Andrea http://orcid.org/0000-0001-7693-2013
Murkli, Steven http://orcid.org/0000-0003-1563-0139
McNeill, John N. http://orcid.org/0000-0002-8401-2388
Yao, Wei http://orcid.org/0000-0002-4229-0486
Sullivan, Matthew http://orcid.org/0000-0002-8112-2848
Gilson, Michael K. http://orcid.org/0000-0002-3375-1738
Chiu, Michael W.
Isaacs, Lyle http://orcid.org/0000-0002-4079-332X
Gibb, Bruce C. http://orcid.org/0000-0002-4478-4084
Mobley, David L. http://orcid.org/0000-0002-1083-5533
Chodera, John D. http://orcid.org/0000-0003-0542-119X
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30 CA008748)
National Science Foundation (CHE-1404911)
National Institutes of Health (1R01GM108889-01)
National Science Foundation (CHE 1352608)
- License Information
-
More Information
Article History
Received: 31 July 2018
Accepted: 7 October 2018
First Online: 10 November 2018
Compliance with ethical standards
:
: JDC was a member of the Scientific Advisory Board for Schrödinger, LLC during part of this study. JDC and DLM are current members of the Scientific Advisory Board of OpenEye Scientific Software. The Chodera laboratory receives or has received funding from multiple sources, including the National Institutes of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, the Molecular Sciences Software Institute, the Starr Cancer Consortium, Cycle for Survival, a Louis V. Gerstner Young Investigator Award, and the Sloan Kettering Institute. A complete funding history for the Chodera lab can be found at. MKG has an equity interest in and is a cofounder and scientific advisor of VeraChem LLC.
